文献速递神经胸部MR

非小细胞肺癌初始分期无脑转移患者的脑转移累积发生率及危险因素分析

Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
PubMed 文献 · AJR Am J Roentgenol · 2021-05-26

本研究回顾性纳入1495例初始评估(含脑MRI)无脑转移的非小细胞肺癌患者,随访脑MRI由转诊医生决定。中位12.3个月时4.8%发生脑转移,临床III-IV期和EGFR突变阳性腺癌是独立危险因素。对临床III-IV期或EGFR突变阳性腺癌患者,初始评估后12个月行监测脑MRI可能合理。

要点

  • 临床III-IV期或EGFR突变阳性腺癌是非小细胞肺癌脑转移的独立危险因素。
  • 初始评估后12个月累积发生率在III-IV期患者为3.9%,EGFR突变阳性腺癌为2.5%。
  • 发生脑转移的患者中44.4%无神经系统症状,58.3%胸部原发病稳定。

核心结论

  • 临床III-IV期和EGFR突变阳性腺癌是非小细胞肺癌患者发生脑转移的独立危险因素。
  • 对临床III-IV期或EGFR突变阳性腺癌患者,初始评估后12个月行监测脑MRI可能合理。

研究设计与样本

  • 回顾性研究纳入1495例初始评估(含脑MRI)无脑转移的非小细胞肺癌患者,平均年龄65±10岁,男性920例、女性575例。
  • 随访脑MRI由转诊医生酌情安排,结合临床记录判断脑转移发生,未行MRI者视为末次临床随访前未发生脑转移。
  • 采用竞争风险模型(死亡为竞争风险)计算脑转移累积发生率,并按临床分期、细胞类型和EGFR突变状态分层。
  • 进行单因素和多因素Cox比例风险回归分析。

诊断标准与关键数值

  • 全组中位12.3个月脑转移发生率为4.8%(72/1495),6、12、18、24个月累积发生率分别为0.6%、2.1%、4.2%、6.8%。
  • 临床III-IV期患者6、12、18、24个月累积发生率分别为1.3%、3.9%、7.7%、10.9%,高于I-II期的0.0%、0.8%、1.2%、2.6%(p < .001)。
  • EGFR突变阳性腺癌患者6、12、18、24个月累积发生率分别为0.7%、2.5%、6.3%、12.3%,高于EGFR突变阴性腺癌的0.4%、1.8%、2.9%、4.4%(p < .001)。
  • 在1109例腺癌患者中,脑转移独立危险因素为临床III-IV期(HR 9.39,p < .001)和EGFR突变阳性(HR 1.78,p = .04)。
  • 研究期间脑转移发生率在临床III-IV期患者中为8.7%,在EGFR突变阳性腺癌患者中为17.4%。

临床应用与阅片要点

  • 对临床III-IV期或EGFR突变阳性腺癌的非小细胞肺癌患者,可考虑初始评估后12个月行监测脑MRI。
  • 发生脑转移的患者中近半数无神经系统症状且胸部原发病稳定,提示监测不应仅依赖症状或胸部影像变化。

局限性

  • 仅17.3%(258/1495)患者接受了随访脑MRI,未行MRI者被默认未发生脑转移,可能低估脑转移发生率。
  • 随访脑MRI由转诊医生酌情安排,存在选择偏倚。
  • 为单中心回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Although established guidelines give indications for performing staging brain MRI at initial diagnosis of non-small cell lung cancer (NSCLC), guidelines are lacking for performing surveillance brain MRI for patients without brain metastases at presentation. OBJECTIVE. The purpose of this study is to estimate the cumulative incidence of and risk factors for brain metastasis development in patients with NSCLC without brain metastases at initial presentation. METHODS. This retrospective study included 1495 patients with NSCLC (mean [± SD] age, 65 ± 10 years; 920 men and 575 women) without brain metastases at initial evaluation that included brain MRI. Follow-up brain MRI was ordered at the discretion of the referring physicians. MRI examinations were reviewed in combination with clinical records for brain metastasis development; patients not undergoing MRI were deemed to have not had metastases develop through last clinical follow-up. The cumulative incidence of brain metastases was determined, with death considered a competing risk, and was stratified by clinical stage group, cell type, and epidermal growth factor receptor (EGFR) gene mutation status. Univariable and multivariable Cox proportional hazards regression analyses were performed. RESULTS. A total of 258 of 1495 patients (17.3%) underwent follow-up brain MRI, and 72 (4.8%) had brain metastases develop at a median of 12.3 months after initial diagnosis of NSCLC. Of the 72 patients who had metastases develop, 44.4% had no neurologic symptoms, and 58.3% had stable primary thoracic disease. The cumulative incidence of brain metastases at 6, 12, 18, and 24 months after initial evaluation was 0.6%, 2.1%, 4.2%, and 6.8%, respectively. Cumulative incidence at 6, 12, 18, and 24 months was higher (p < .001) in patients with clinical stage III-IV disease (1.3%, 3.9%, 7.7%, and 10.9%, respectively) than in those with clinical stage I-II disease (0.0%, 0.8%, 1.2%, and 2.6%, respectively), and it was higher (p < .001) in patients with EGFR mutation-positive adenocarcinoma (0.7%, 2.5%, 6.3%, and 12.3%, respectively) than in those with EGFR mutation-negative adenocarcinoma (0.4%, 1.8%, 2.9%, and 4.4%, respectively). Among 1109 patients with adenocarcinoma, independent risk factors for the development of brain metastasis were clinical stage III-IV (hazard ratio [HR], 9.39; p < .001) and EGFR mutation-positive status (HR, 1.78; p = .04). The incidence of brain metastasis over the study interval was 8.7% among patients with clinical stage III-IV disease and 17.4% among those with EGFR mutation-positive adenocarcinoma. CONCLUSION. Clinical stage III-IV and EGFR mutation-positive adenocarcinoma are independent risk factors for brain metastasis development. CLINICAL IMPACT. For patients with clinical stage III-IV disease or EGFR mutation-positive adenocarcinoma, surveillance brain MRI performed 12 months after initial evaluation may be warranted.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Kim M, Suh CH, Lee SM, et al. Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis. AJR Am J Roentgenol. 2021. PMID: 34037408. doi:10.2214/AJR.21.25787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。